Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.
Elodie PronierRobert L BowmanJihae AhnJacob GlassCyriac KandothTiffany R MerlinskyJustin T WhitfieldBenjamin H DurhamAntoine GruetAmritha Varshini Hanasoge SomasundaraRaajit RampalAri MelnickRichard P KocheBarry S TaylorRoss L LevinePublished in: Blood (2018)
Genetic studies have identified recurrent somatic mutations in acute myeloid leukemia (AML) patients, including in the Wilms' tumor 1 (WT1) gene. The molecular mechanisms by which WT1 mutations contribute to leukemogenesis have not yet been fully elucidated. We investigated the role of Wt1 gene dosage in steady-state and pathologic hematopoiesis. Wt1 heterozygous loss enhanced stem cell self-renewal in an age-dependent manner, which increased stem cell function over time and resulted in age-dependent leukemic transformation. Wt1-haploinsufficient leukemias were characterized by progressive genetic and epigenetic alterations, including those in known leukemia-associated alleles, demonstrating a requirement for additional events to promote hematopoietic transformation. Consistent with this observation, we found that Wt1 depletion cooperates with Flt3-ITD mutation to induce fully penetrant AML. Our studies provide insight into mechanisms of Wt1-loss leukemogenesis and into the evolutionary events required to induce transformation of Wt1-haploinsufficient stem/progenitor cells.
Keyphrases
- acute myeloid leukemia
- genome wide
- copy number
- stem cells
- dna methylation
- gene expression
- bone marrow
- end stage renal disease
- multiple sclerosis
- allogeneic hematopoietic stem cell transplantation
- transcription factor
- chronic kidney disease
- neoadjuvant chemotherapy
- radiation therapy
- squamous cell carcinoma
- peritoneal dialysis
- locally advanced
- wild type